Open AccessThe tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patients
Author(s) -
Manuela Pogliaghi,
Laura Papagno,
Sidonie Lambert,
Ruxandra Câlin,
Vincent Cálvez,
Christine Katlama,
Brigitte Autran
Publication year - 2014
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000000073
Subject(s) - dasatinib , tyrosine kinase , in vitro , immune system , tyrosine kinase inhibitor , virology , human immunodeficiency virus (hiv) , immunology , biology , medicine , signal transduction , microbiology and biotechnology , biochemistry , cancer
HIV reservoirs persistence despite antiretroviral therapy (ART) might be related to persistent immune activation and residual HIV production, requiring further therapeutic strategies. We demonstrated that the tyrosine kinase inhibitor (TKI) Dasatinib, used for chronic myeloid leukaemia, significantly blocks in vitro HIV1 production by 3.4 logs in HIV1-infected primary CD4 T lymphocytes, by inhibiting cell activation and proliferation, without cell toxicity. This molecule deserves to be investigated further for HIV cure strategies to hinder persistent immune activation and residual viral production.